New hope for rare stomach cancer: chemo drug shows promise in early trial
NCT ID NCT05661643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug temozolomide in people with a rare type of advanced stomach cancer called SDH-deficient GIST. About 29 adults will receive the drug to see if it shrinks tumors and is safe. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, Seoul, 138-736, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST
- Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST